[go: up one dir, main page]

DE60128801D1 - Isoflavonen gegen strahlungsinduzierte Mortalität - Google Patents

Isoflavonen gegen strahlungsinduzierte Mortalität

Info

Publication number
DE60128801D1
DE60128801D1 DE60128801T DE60128801T DE60128801D1 DE 60128801 D1 DE60128801 D1 DE 60128801D1 DE 60128801 T DE60128801 T DE 60128801T DE 60128801 T DE60128801 T DE 60128801T DE 60128801 D1 DE60128801 D1 DE 60128801D1
Authority
DE
Germany
Prior art keywords
isoflavones
against radiation
induced mortality
present
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60128801T
Other languages
English (en)
Other versions
DE60128801T2 (de
Inventor
Michael R Landauer
Thomas Michael Seed
Venkataraman Srinivasan
Alla Shapiro
Chris H Takimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States, Represented By T Us
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Uniformed Services University of Health Sciences
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniformed Services University of Health Sciences, US Department of Health and Human Services filed Critical Uniformed Services University of Health Sciences
Priority claimed from PCT/US2001/019089 external-priority patent/WO2001095937A2/en
Publication of DE60128801D1 publication Critical patent/DE60128801D1/de
Application granted granted Critical
Publication of DE60128801T2 publication Critical patent/DE60128801T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092Details
    • A61N2005/1094Shielding, protecting against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
DE60128801T 2000-06-14 2001-06-12 Isoflavone gegen strahlungsinduzierte Sterblichkeit Expired - Lifetime DE60128801T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21137500P 2000-06-14 2000-06-14
US211375P 2000-06-14
US22373400P 2000-08-08 2000-08-08
US223734P 2000-08-08
PCT/US2001/019089 WO2001095937A2 (en) 2000-08-08 2001-06-12 Phytoestrogenic isoflavone compositions

Publications (2)

Publication Number Publication Date
DE60128801D1 true DE60128801D1 (de) 2007-07-19
DE60128801T2 DE60128801T2 (de) 2008-06-26

Family

ID=38015255

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60128801T Expired - Lifetime DE60128801T2 (de) 2000-06-14 2001-06-12 Isoflavone gegen strahlungsinduzierte Sterblichkeit

Country Status (8)

Country Link
US (2) US7655694B2 (de)
EP (1) EP1289556B1 (de)
JP (2) JP4995396B2 (de)
AT (1) ATE363902T1 (de)
AU (1) AU2001271310B2 (de)
CA (1) CA2412501C (de)
DE (1) DE60128801T2 (de)
ES (1) ES2288169T3 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2820974B1 (fr) * 2001-02-21 2004-02-13 Pharmascience Lab Composition topique comprenant une solution vraie contenant un derive de chromane ou de chromene, son procede de preparation et son utilisation cosmetique et therapeutique
US20080089960A1 (en) * 2006-10-16 2008-04-17 Miri Seiberg Use of Legume Products for the Treatment and Prevention of Radiotherapy-Induced Skin Damage
KR101017650B1 (ko) * 2008-03-04 2011-02-25 한국원자력연구원 헤스페리딘 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 세포 보호용 조성물
US8900635B2 (en) 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
US9623003B1 (en) 2013-04-04 2017-04-18 Humanetics Corporation Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein
US9084726B2 (en) 2013-11-26 2015-07-21 Humanetics Corporation Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5914345A (en) * 1994-10-11 1999-06-22 Endoluminal Therapeutics, Inc. Treatment of tissues to reduce subsequent response to injury
US5824702A (en) * 1996-06-07 1998-10-20 Mount Sinai School Of Medicine Of The City University Of New York Genistein as a preventive against ultraviolet induced skin photodamage and cancer
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6132795A (en) * 1998-03-15 2000-10-17 Protein Technologies International, Inc. Vegetable protein composition containing an isoflavone depleted vegetable protein material with an isoflavone containing material
FR2781156B1 (fr) 1998-07-20 2001-06-29 Lafon Labor Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
US6426362B1 (en) * 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
AU2001271296A1 (en) 2000-06-14 2001-12-24 Alla Shapiro Radioprotective agents

Also Published As

Publication number Publication date
ATE363902T1 (de) 2007-06-15
US8349888B2 (en) 2013-01-08
JP2004538242A (ja) 2004-12-24
JP5551674B2 (ja) 2014-07-16
US20100197779A1 (en) 2010-08-05
AU2001271310B2 (en) 2005-10-06
DE60128801T2 (de) 2008-06-26
US7655694B2 (en) 2010-02-02
CA2412501C (en) 2011-05-31
CA2412501A1 (en) 2001-12-20
ES2288169T3 (es) 2008-01-01
JP4995396B2 (ja) 2012-08-08
EP1289556A2 (de) 2003-03-12
US20040238781A1 (en) 2004-12-02
JP2012067123A (ja) 2012-04-05
EP1289556B1 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
BR0204869B1 (pt) unidade local de um aparelho de tratamento de ar e aparelho de tratamento de ar.
ATE478670T1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
CY1107439T1 (el) Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα
AU2003220970A1 (en) Diamino-pyrimidines and their use as angiogenesis inhibitors
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
ATE448232T1 (de) Substituierte heterozyklen
MXPA05004247A (es) Cromonas y derivados de cromona y usos de los mismos.
ATE400577T1 (de) Anellierte dihydropyrane
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
DK1250328T4 (da) Dihydro-1,3,5-triazindiaminderivater og terapeutisk anvendelse deraf
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
DE60128801D1 (de) Isoflavonen gegen strahlungsinduzierte Mortalität
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
CY1106211T1 (el) Φαρμακευτικα παρασκευασματα πepιεχοντας εκχυλισματα της ισοφλαβονης της σογιας και προβιοτικους μικροοργανισμους
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
WO2001095937A3 (en) Phytoestrogenic isoflavone compositions
ATE383874T1 (de) Perylenequinonen zur anwendung als sonosensitizer
NO20012634L (no) Nye kreftbehandlinger
ATE400285T1 (de) Mischungen von isoflavonen und flavonen
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
ES2185605T3 (es) 2,3-dihidro-1h-5,9-dioxaciclohepta (f) inden-7-onas 1,2-sustituidas y benzo (b) (1,4)dioxepin-3 onas 7-sustituidas.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANC, US

Owner name: THE UNITED STATES OF AMERICA, REPRESENTED BY T, US

8328 Change in the person/name/address of the agent

Representative=s name: MUELLER-BORE & PARTNER, PATENTANWAELTE, EUROPEAN P

8364 No opposition during term of opposition